Provider adherence to aspirin prophylaxis prescription guidelines for preeclampsia
Recommended Citation
Obstetrics, Gynecology and Women’s Health Services Ayyash M, Goyert G, Pitts D, Khangura R, Garcia R, Jacobsen G, and Shaman M. Provider adherence to aspirin prophylaxis prescription guidelines for preeclampsia. Pregnancy Hypertens 2023; 34:1-4.
Document Type
Article
Publication Date
9-9-2023
Publication Title
Pregnancy Hypertens
Abstract
OBJECTIVE: To evaluate provider adherence to aspirin prophylaxis prescription guidelines for patients at risk.
STUDY DESIGN: A retrospective chart review was performed at Henry Ford Health (HFH) between October 2015 and December 2020. In October 2015, low-dose aspirin was recommended for women who met high risk criteria for preeclampsia at HFH; in February 2019, aspirin recommendation expanded to include women who met either moderate or high-risk criteria. A total of 46,016 pregnancies occurred between Oct 2015 and Dec 2020 of which 15,167 (33.0%) met high and moderate risk criteria.
RESULTS: From the population at risk, 1,255 (8.3%) had a history of preeclampsia, 2,534 (16.7%) had a history of chronic hypertension, 1,418 (9.3%) had a history of diabetes, 7,470 (49.3%) were nulliparous, 4,038 (26.6%) were 35 years of age or older, 6,395 (42.2%) had a body mass index greater than 30 kg/m2, and 8,174 (54.5%) were African Americans. Only 630 out of 3,584 (17.6%) of women meeting the high-risk criteria for preeclampsia between Oct 2015 and Jan 2019 received low-dose aspirin and only 891 out of 5,874 (15.2%) of women meeting the high or moderate risk criteria for preeclampsia between Feb 2019 and Dec 2020 received low-dose aspirin prophylaxis.
CONCLUSION: Adherence to aspirin prophylaxis guidelines was low. Most urban healthcare systems serve diverse, high-risk populations with multiple comorbidities rendering many women at risk for preeclampsia. Educational efforts to improve provider knowledge regarding this important preventative measure are indicated. Recommendation for implementing universal aspirin in such high-risk populations should also be considered.
PubMed ID
37696232
Volume
34
First Page
1
Last Page
4